Definium Therapeutics, Inc.
DFTX
Get informed when a big investor buys or sells
+ FollowMarket Cap$4.9B
Close$
$2.89
91.6% downside
Current Fair Value
91.6% downsideOvervalued by 91.6% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $4.90 Billion |
|---|---|
| Enterprise Value | $4.24 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-2.06 |
| Beta | 2.19 |
| Outstanding Shares | 110,684,720 |
Return
| Return on Equity | -38.51% |
|---|---|
| Return on Assets | -31.79% |
| Return on Invested Capital | -23.56% |
Valuation & Multiples
| P/E Ratio | -10.73 |
|---|---|
| PEG | -3.94 |
| Price to Sales | - |
| Price to Book Ratio | 4.28 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -18.84 |
| Enterprise Value to Net Income | -12 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 6, 2026
EPS Estimate
$-0.54
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
November 5, 2026
EPS Estimate
$-0.56
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 39.88% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.04%▼ 104.68% |
|---|---|
| Total Invested | $1.59M▼ 99.97% |
| Investors Holding | 8▼ 381.00% |
ESG Score
No data
About Definium Therapeutics, Inc.
74 employees
CEO: Robert Barrow Definium Therapeutics, Inc. is a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized...